TWC
ARQT icon

TD Waterhouse Canada’s Arcutis Biotherapeutics ARQT Stock Holding History

TD Waterhouse Canada’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.23K Hold
318
– – ﹤0.01% 1874
2026
Q1 		$7.63K Hold
318
– – ﹤0.01% 1821
2025
Q4 		$9.23K Hold
318
– – ﹤0.01% 1572
2025
Q3 		$6.3K Hold
318
– – ﹤0.01% 1637
2025
Q2 		$4.36K Hold
318
– – ﹤0.01% 1621
2025
Q1 		$4.74K Hold
318
– – ﹤0.01% 1552
2024
Q4 		$4.42K Buy
+318
New +$3.48K ﹤0.01% 1585

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

TD Waterhouse Canada's ARQT Position: Q2 2026 in Review

TD Waterhouse Canada held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 318 shares worth $8.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

TD Waterhouse Canada first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $9.23K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • TD Waterhouse Canada held 318 shares of Arcutis Biotherapeutics worth $8.23K as of Q2 2026.
  • TD Waterhouse Canada left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #1874 holding.
  • TD Waterhouse Canada first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • TD Waterhouse Canada's Arcutis Biotherapeutics position peaked at $9.23K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.